Profil
Michael Heartlein is the founder of Translate Bio, Inc., which was founded in 2011.
He held the title of Executive Vice President from 2019 to 2020.
Dr. Heartlein also worked at Shire Human Genetic Therapies, Inc. from 2003 to 2016 as the Head-Messenger RNA Therapeutic.
Dr. Heartlein received his undergraduate degree from Illinois State University in 1980 and his doctorate degree from Oak Ridge Graduate School of Biomedical Sciences in 1984.
Anciens postes connus de Michael Heartlein
| Sociétés | Poste | Fin |
|---|---|---|
| TRANSLATE BIO, INC. | Fondateur | 01/06/2020 |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Corporate Officer/Principal | 01/12/2016 |
Formation de Michael Heartlein
| Illinois State University | Undergraduate Degree |
| Oak Ridge Graduate School of Biomedical Sciences | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
